Brand Name	Generic Name	FDA Approval	Indication	Administration	Exclusion Reason
Lucentis	Ranibizumab	6/30/2006	Macular degeneration	Intravitreal	Part B
Soliris	Eculizumab	3/16/2007	Paroxysmal nocturnal hemoglobinuria	IV infusion	Part B
Entereg	Alvimopan	5/20/2008	Aids recovery of bowel resection surgery	PO post-op	Part A
Cleviprex	Clevidipine	8/1/2008	Blood pressure control when oral therapy not feasible	IV infusion	Part B
Nplate	Romiplostim	8/22/2008	Idiopathic (immune) thrombocytopenic purpura	Subcutaneous	Part B
Lusedra	Fospropofol	12/12/2008	Sedation	IV infusion	Part B
Kalbitor	Ecallantide	12/1/2009	Hereditary angioedema	Subcutaneous	Part B
Xiaflex	Collagenase clostridium histolyticum	2/2/2010	Dupuytren’s disease	Injection	Part A/B
Asclera	Polidocanol	3/30/2010	Varicose veins	IV injection	Part A/B
Krystexxa	Pegloticase	9/14/2010	Hyperuricemia/gout	IV infusion	Part B
Adcetris	Brentuximab vedotin	8/19/2011	Hodgkin lymphoma (third-line agent)	IV infusion	Part B
Eylea	Aflibercept	11/18/2011	Macular degeneration	Intravitreal	Part B
Kyprolis	Carfilzomib	7/20/2012	Multiple myeloma (third-line agent)	IV infusion	Part B
Jetrea	Ocriplasmin	10/17/2012	Vitreomacular adhesion	Intravitreal	Part B

FDA = U.S. Food and Drug Administration; IV = intravenous; PO = per oral.